448896-40-0

Upstream product

• 3442-82-8 1,3-bis(trimethylsilyl)uracil 

Downstream Products

• 287933-77-1 1-((1R,2R,3R)-tetrahydro-2-(1,1-dimethylethyldiphenyl)-silyloxy-3-(1,1-dimethylethyldiphenyl)-silyloxymethyl-1-furanyl)-4-(1,2,4-triazol-1-yl)-2(1H)-pyrimidinone 
• 448896-42-2 4-amino-1-((1R,2R,3R)-tetrahydro-2-(1,1-dimethylethyldiphenyl)-silyloxy-3-(1,1-dimethylethyldiphenyl)-silyloxymethyl-1-furanyl)-2(1H)-pyrimidinone 
• 448896-41-1 1-((1R,2R,3R)-tetrahydro-2-(1,1-dimethylethyldiphenyl)-silyloxy-3-(1,1-dimethylethyldiphenyl)-silyloxymethyl-1-furanyl)-2,4(1H,3H)-pyrimidinedione 
• 287933-76-0 1-((1R,2R,3R)-tetrahydro-2-hydroxy-3-(1,1-dimethylethyldiphenyl)-silyloxymethyl-1-furanyl)-2,4(1H,3H)-pyrimidinedione 

Relevant academic research and scientific papers

Synthesis and biological activity of a series of methylene-expanded oxetanocin nucleoside analogues

A series of methylene-expanded oxetanocin nucleoside analogues, e.g. analogues of 2 and the known antiviral nucleosides AZT, FLT, and ddC (3) were prepared by a very direct route beginning with the readily available (S)-glycidol 4 and proceeding via the dihydrofuran-3-methanols 9a,b. Biological testing of these modified nucleosides indicates that they are non-cytotoxic compounds with generally weak antiviral activity. However, the guanosine analogue 2G showed pronounced activity vs. herpes simplex virus type 1 (HSV-1) in cell culture and was HSV-1-encoded thymidine kinase dependent. This compound is therefore an interesting new lead structure for the development of new anti-HSV agents.